Adocia

29 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Nov 2031

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

2 fees due Jan 2 to 25, 2027 · next Jan 2
1 fee due Feb 20, 2027
The maintenance fee for Injectable solution at pH 7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals (US 10,383,920) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
1 fee due May 5, 2027
The maintenance fee for Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid (US 10,463,717) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.
1 fee due Jun 1, 2027
The maintenance fee for Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid (US 9,198,971) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
1 fee due Jul 30, 2027
The maintenance fee for Injectable PH 7 Solution Comprising at Least One Basal Insulin Having a Pi from 5.8 to 8.5 and a Co-Polyamino Acid Bearing Carboxylate Charges and Hydrophobic Radicals (US 11,883,496) comes due Jul 30, 2027. Unpaid by Jan 31, 2028, it lapses early.
1 fee due Aug 4, 2027
The maintenance fee for Injectable solution at pH7 comprising at least one basal insulin the pI of which is from 5.8 to 8.5, a prandial insulin and/or a gastrointestinal hormone, and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals (US 10,548,952) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
2 fees due Sep 8 to 10, 2027 · next Sep 8
1 fee due Oct 7, 2027
The maintenance fee for Compositions in the Form of an Injectable Aqueous Solution Including at Least Human Insulin A21G and a Glucagon Suppressor with Prandial Action (US 10,610,572) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.
1 fee due Nov 12, 2027
The maintenance fee for Rapid-acting insulin formulation comprising a substituted anionic compound (US 10,646,551) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,492,467	Rapid-acting insulin formulation comprising an oligosaccharide In force Ends no later than Nov 2, 2031 · From the USPTO record	In force	Ends no later than Nov 2, 2031	From the USPTO record
US 9,018,190	Functionalized oligosaccharides In force Term ends Feb 27, 2032 · From the USPTO record	In force	Term ends Feb 27, 2032	From the USPTO record
US 9,198,971	Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid In force Term ends Jan 9, 2033 · From the USPTO record	In force	Term ends Jan 9, 2033	From the USPTO record
US 10,335,489	Injectable solution at pH 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid In force Term ends Sep 17, 2033 · From the USPTO record	In force	Term ends Sep 17, 2033	From the USPTO record
US 10,583,175	Rapid-acting insulin formulation comprising a substituted anionic compound In force Ends no later than Nov 13, 2033 · From the USPTO record	In force	Ends no later than Nov 13, 2033	From the USPTO record
US 10,646,551	Rapid-acting insulin formulation comprising a substituted anionic compound In force Term ends Nov 13, 2033 · From the USPTO record	In force	Term ends Nov 13, 2033	From the USPTO record
US 10,881,716	Rapid-acting insulin formulation comprising a substituted anionic compound In force Ends no later than Nov 13, 2033 · From the USPTO record	In force	Ends no later than Nov 13, 2033	From the USPTO record
US 11,324,808	Rapid-acting insulin formulation comprising a substituted anionic compound In force Ends no later than Nov 13, 2033 · From the USPTO record	In force	Ends no later than Nov 13, 2033	From the USPTO record
US 9,493,583	Anionic polysaccharides functionalized by a hydrophobic acid derivative In force Term ends Jun 12, 2034 · From the USPTO record	In force	Term ends Jun 12, 2034	From the USPTO record
US 9,278,131	Process for lowering the viscosity of highly concentrated protein solutions In force Term ends Jun 27, 2034 · From the USPTO record	In force	Term ends Jun 27, 2034	From the USPTO record

10 of 29 patents shown.

Pro members see all 29.

Pro members: see all 29 patents

Also on record, not counted in the 29: 14 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 1 abandoned · 47 no status recorded

List them